Cardiff Oncology Inc (NASDAQ:CRDF) price closed higher on Friday, February 21, and jumping 1.06% above its previous close.
A look at the daily price movement shows that the last close reads $4.70. Taking into account the 52-week price action we note that the stock hit a 52-week high of $6.42 and 52-week low of $1.65. The stock added 34.18% on its value in the past month.
Cardiff Oncology Inc, which has a market valuation of $315.96 million, is expected to release its quarterly earnings report in March.
The average estimate suggests sales growth for the quarter will likely fall by -39.63% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of 610.67k for the company’s annual revenue in current year. Per this projection, the revenue is forecast to grow 25.14% above that which the company brought in the current year earning report.
Technical indicators in stocks provide crucial insights into market trends, guiding investors with precise entry and exit points based on price movements for informed decision-making.On the technical perspective front, indicators give CRDF a short term outlook of 100% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 100% Buy.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 1 analysts have assigned CRDF a recommendation rating as follows: 0 rate it as a Hold; 1 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Cardiff Oncology Inc (CRDF) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that CRDF’s price is at present 13.50% off the SMA20 and 17.92% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 62.77, with weekly volatility standing at 10.49%. The indicator jumps to 8.41% when calculated based on the past 30 days. Cardiff Oncology Inc (NASDAQ:CRDF)’s beta value is holding at 1.73, while the average true range (ATR) indicator is currently reading 0.37.
An analysis of the Cardiff Oncology Inc (NASDAQ:CRDF) stock in terms of its daily trading volume indicates that the 3-month average is 2.12 million.
Current records show that the company has 66.52M in outstanding shares. The insiders’ percentage holdings are 10.14% of outstanding shares while the percentage share held by institutions stands at 34.46%. But the 9.45% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
